Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: A diagnostic adjunct in the determination of primary site

American Journal of Clinical Pathology

Volumn 107, Issue 1, 1997, Pages 12-19

  Brown, Richard W ^a   Campagna, Lauri Brozo ^a   Dunn, J Kay ^a   Cagle, Philip T ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Immunohistochemistry; Metastases; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CELLULAR DISTRIBUTION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; METASTASIS; OMENTUM; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SOFT TISSUE CANCER;

EID: 0031043525     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.1.12     Document Type: Article

References (32)

1. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257-263.
2. Daugaard G. Unknown primary tumors. Cancer Treat Rev. 1994; 20:119-147.
3. Nadji M, Tabei SZ, Castro A, Chu TM, Morales A. Prostatic origin of tumors: an immunohistochemical study. Am J Clin Pathol. 1980;73:735-739.
4. Papsidero LD, Croghan GA, Asirwatham J, et al. Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5. Am J Pathol. 1985;121:451-454.
5. De Micco C, Ruf J, Carayon P, et al. Immunohistochemical study of thyroglobulin in thyroid carcinomas with monoclonal antibodies. Cancer. 1987; 59:471-176.
6. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986;46:3118-3124.
7. Loy TS, Nashelsky MB. Reactivity of B72.3 with adenocarcinomas: an immunohistochemical study of 476 cases. Cancer. 1993;72:2495-2498.
8. Mesa-Tejada R, Palakodety RB, Leon JA, Khatcherian AO, Greaton CJ. Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. Am J Pathol. 1988;130:305-314.
9. Loy TS, Chapman RK, Diaz-Arias AA, Bulatao IS, Bickel JT. Distribution of BCA-225 in adenocarcinomas: an immunohistochemical study of 446 cases. Am J Clin Pathol. 1991;96: 326-329.
10. Ma CK, Zarbo RJ, Frierson HF, Lee MVV. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol. 1993;99:551-557.
11. Akasofu M, Kawahara E, Kurumaya H, Nakanishi I. Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver. Acta Pathol Jpn. 1993;43:736-744.
12. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast carcinoma. Hum Pathol. 1989;20:281-287.
13. Raab SS, Berg LC, Swanson PE, Wick MR. Adenocarcinoma in the lung in patients with breast cancer: a prospective analysis of the discriminatory value of immunohistology. Am J Clin Pathol. 1993;100:27-35.
14. Wick MR. Monoclonal antibodies to carcinoembryonic antigen in diagnostic immunohistochemistry. In: Wick MR, Siegal GD, eds. Monoclonal Antibodies in Diagnostic Immunohistochemistry. New York, NY: Marcel Dekker: 1988;539-567.
15. Sheahan K, O'Brien MJ, Burke B, et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol. 1990;94:157-164.
16. Dietel M, Arps H, Klapdor R, et al. Antigen detection by the monoclonal antibodies CA19-9 and CA125 in normal and tumor tissue and patients' sera. J Can Res Clin Oncol. 1986; 111:257-265.
17. Loy TS, Sharp SC, Andershock CJ, Craig SB. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas: an immunohistochemical study of 527 cases. Am J Clin Pathol. 1993;99:726-728.
18. Gatalica Z, Miettinen M. Distribution of carcinoma antigens CA19-9 and CA 15-3: an immunohistochemical study of 400 tumors. Appl Immunohistochem. 1994;2:205-211.
19. Koelma IA, Nap M, Rodenburg CJ, Fleuren GJ. The value of tumor marker CA125 in surgical pathology. Histopathology. 1987;11:287-294.
20. Loy TS, Quesenberry JT, Sharp SC. Distribution of CA125 in adenocarcinomas: an immunohistochemical study of 481 cases. Am J Clin Pathol. 1992;98:175-179.
21. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641-651.
22. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol. 1987;18:946-954.
23. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993;24:347-354.
24. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
25. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based upon microwave heating of tissue sections. J Histochem Cytochem. 1991;39:741-748.
26. Brown RW, Chirala R. Utility of microwave-citrate antigen retrieval in diagnostic immunohistochemistry. Mod Pathol. 1995;8:515-520.
27. Battifora H. Assessment of antigen damage in immunohistochemistry: the vimentin internal control. Am J Clin Pathol. 1991;96:669-671.
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley, 1989.
29. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
30. Mauri FA, Veronese S, Frigo B, et al. ER1D5 and H222 (ER-ICA) antibodies to human estrogen receptor in breast carcinomas: results of a multicentric comparative study. Appl Immunohistochem. 1994;2:157-163.
31. Ellis IO, Hitchcock A. Tumor marker immunoreactivity in adenocarcinoma. J Clin Pathol. 1988;41:1964.
32. Gamble AR, Bell JA, Pearson D, Ellis IO. Use of tumor marker immunohistochemistry to identify primary site of metastatic tumor. Br Med J. 1993;306:295-298.